Monday, August 24
Gene therapy trial halted after spinal growths found in patients
A safety scare in a rare-disease study sent one biotech stock into freefall, while a court ruling handed another company a quarter-billion-dollar bill.
Top Stories
Regenxbio's gene therapy program is effectively in crisis after a federal safety halt
The FDA froze Regenxbio's Hunter syndrome gene therapy trial after doctors found nodules and masses on the spines of five patients, immediately stopping new enrollments and any further dosing.
This is not a paperwork setback — a spinal safety signal in a small trial is the kind of finding that can permanently derail a program, and this was Regenxbio's lead asset.
Guardant Health now owes a quarter-billion dollars for technology it should have licensed
A Delaware federal judge finalized a ruling requiring Guardant Health to pay over $245 million in royalties to TwinStrand Biosciences and the University of Washington, locking in a jury verdict from nearly two years ago for willful patent infringement.
The word "willful" matters here — courts reserve that finding for defendants who knew they were infringing and did it anyway, which typically signals the maximum penalty rather than a negotiated middle ground.
SpaceX's AI satellite ambitions are real, but the valuation leaves no room for delays
SpaceX announced plans to put Nvidia-powered AI satellites into orbit by the end of next year, staking a claim in what would essentially be a data center floating above the Earth, while ARK Invest poured $27 million into the stock on Friday, making it the firm's second-largest holding.
The problem is that at 93 times forward earnings, every Starship delay or Starlink margin squeeze gets punished immediately, which is exactly why the stock slipped even on genuinely exciting news.
Also Today
- PDD's revenue growth missed expectations despite a strong cash cushion
- UPS bets $2 billion on higher-margin international and healthcare routes
- GSK wins two regulatory approvals in Japan and the United States
Takeaway
Today's market conversation was dominated by clinical and legal risk landing on two healthcare companies at once, a reminder that the biggest single-day moves rarely come from macro forces.
Watch for any Regenxbio update on whether the FDA's clinical hold is narrow and fixable or the beginning of a broader safety review of the gene therapy's delivery mechanism.
